171 related articles for article (PubMed ID: 34900698)
1. Lenvatinib Plus PD-1 Inhibitors as First-Line Treatment in Patients With Unresectable Biliary Tract Cancer: A Single-Arm, Open-Label, Phase II Study.
Zhang Q; Liu X; Wei S; Zhang L; Tian Y; Gao Z; Jin M; Yan S
Front Oncol; 2021; 11():751391. PubMed ID: 34900698
[TBL] [Abstract][Full Text] [Related]
2. Sintilimab plus Lenvatinib conversion therapy for intermediate/locally advanced hepatocellular carcinoma: A phase 2 study.
Wang L; Wang H; Cui Y; Liu M; Jin K; Xu D; Wang K; Xing B
Front Oncol; 2023; 13():1115109. PubMed ID: 36874115
[TBL] [Abstract][Full Text] [Related]
3. Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results.
Ueno M; Ikeda M; Sasaki T; Nagashima F; Mizuno N; Shimizu S; Ikezawa H; Hayata N; Nakajima R; Morizane C
BMC Cancer; 2020 Nov; 20(1):1105. PubMed ID: 33198671
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of GEMOX plus donafenib and tislelizumab as first-line therapy for advanced epithelial malignant biliary tract cancer.
Wang L; Zhang N; Wang Y; Zhang T; Zhu W; Mao A; Zhao Y; Wang L
Cancer Med; 2023 Jun; 12(11):12263-12271. PubMed ID: 37039263
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of different PD-1 inhibitors in combination with lenvatinib in the treatment of unresectable primary liver cancer: a multicentre retrospective study.
Li QM; Sun QC; Jian Y; He JZ; Zhu HB; Hong C; Zeng L; Li RN; Wang JR; Li Y; Chen LY; Weng X; Liu L; Dong HZ; Xiao LS; Cui H
Discov Oncol; 2023 Jun; 14(1):105. PubMed ID: 37336826
[TBL] [Abstract][Full Text] [Related]
6. A Retrospective Study on Therapeutic Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors Plus Lenvatinib in Patients With Unresectable Hepatocellular Carcinoma.
Teng Y; Ding X; Li W; Sun W; Chen J
Technol Cancer Res Treat; 2022; 21():15330338221075174. PubMed ID: 35313780
[No Abstract] [Full Text] [Related]
7. Effectiveness and safety of radiotherapy plus programmed death-1 inhibitors and lenvatinib in patients with advanced biliary tract carcinoma: a real-world study.
Wang Y; Yang X; Wang Y; Xue J; Zhang N; Yang X; Cong N; Zhang J; Zhu C; Zhang L; Hou X; Zhao H
Cancer Immunol Immunother; 2023 Jul; 72(7):2197-2204. PubMed ID: 36856834
[TBL] [Abstract][Full Text] [Related]
8. Fecal microbiota transplantation plus tislelizumab and fruquintinib in refractory microsatellite stable metastatic colorectal cancer: an open-label, single-arm, phase II trial (RENMIN-215).
Zhao W; Lei J; Ke S; Chen Y; Xiao J; Tang Z; Wang L; Ren Y; Alnaggar M; Qiu H; Shi W; Yin L; Chen Y
EClinicalMedicine; 2023 Dec; 66():102315. PubMed ID: 38024475
[TBL] [Abstract][Full Text] [Related]
9. Safety and feasibility of toripalimab plus lenvatinib with or without radiotherapy in advanced BTC.
Wang Y; Zhang N; Xue J; Zhu C; Wang Y; Zhang L; Yang X; Wang H; Wang S; Chao J; Yang X; Zhao H
Front Immunol; 2023; 14():1084843. PubMed ID: 36733485
[TBL] [Abstract][Full Text] [Related]
10. Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF).
Arkenau HT; Martin-Liberal J; Calvo E; Penel N; Krebs MG; Herbst RS; Walgren RA; Widau RC; Mi G; Jin J; Ferry D; Chau I
Oncologist; 2018 Dec; 23(12):1407-e136. PubMed ID: 29853658
[TBL] [Abstract][Full Text] [Related]
11. Local-regional therapy combined with toripalimab and lenvatinib in patients with advanced biliary tract cancer.
Wang Y; Xun Z; Yang X; Wang Y; Wang S; Xue J; Zhang N; Yang X; Lu Z; Zhou J; Zhou K; Sang X; Zhao H
Am J Cancer Res; 2023; 13(3):1026-1037. PubMed ID: 37034211
[TBL] [Abstract][Full Text] [Related]
12. Triple therapy in biliary tract cancers: GemOX plus immune checkpoint inhibitor in combination with lenvatinib or NGS-guided targeted therapy.
Dong X; Zhang Z; Zhang Q; Chen L; Cao G; Liu C; Song T; Lu W; Zhang W
J Cancer Res Clin Oncol; 2023 May; 149(5):1917-1927. PubMed ID: 35802197
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of radiotherapy combined with lenvatinib plus PD-1 inhibitors as neo-adjuvant therapy in hepatocellular carcinoma with portal vein thrombus: protocol of an open-label, single-arm, prospective, multi-center phase I trial.
Li G; Shu B; Zheng Z; Yin H; Zhang C; Xiao Y; Yang Y; Yan Z; Zhang X; Yang S; Li G; Dong J
Front Oncol; 2022; 12():1051916. PubMed ID: 36505833
[TBL] [Abstract][Full Text] [Related]
14. Lenvatinib Plus Camrelizumab vs. Lenvatinib Monotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study.
Li Q; Cao M; Yuan G; Cheng X; Zang M; Chen M; Hu X; Huang J; Li R; Guo Y; Ruan J; Chen J
Front Oncol; 2022; 12():809709. PubMed ID: 35280760
[TBL] [Abstract][Full Text] [Related]
15. A Retrospective Analysis of Conversion Therapy with Lenvatinib, Sintilimab, and Arterially-Directed Therapy in Patients with Initially Unresectable Hepatocellular Carcinoma.
Gan L; Lang M; Tian X; Ren S; Li G; Liu Y; Han R; Zhu K; Li H; Wu Q; Cui Y; Zhang W; Fang F; Li Q; Song T
J Hepatocell Carcinoma; 2023; 10():673-686. PubMed ID: 37125392
[TBL] [Abstract][Full Text] [Related]
16. A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma.
Hutson TE; Michaelson MD; Kuzel TM; Agarwal N; Molina AM; Hsieh JJ; Vaishampayan UN; Xie R; Bapat U; Ye W; Jain RK; Fishman MN
Eur Urol; 2021 Aug; 80(2):162-170. PubMed ID: 33867192
[TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study.
Chen S; Xu B; Wu Z; Wang P; Yu W; Liu Z; Huang X; Wu Y; Li T; Guo W
BMC Cancer; 2021 Oct; 21(1):1126. PubMed ID: 34670506
[TBL] [Abstract][Full Text] [Related]
18. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.
Makker V; Rasco D; Vogelzang NJ; Brose MS; Cohn AL; Mier J; Di Simone C; Hyman DM; Stepan DE; Dutcus CE; Schmidt EV; Guo M; Sachdev P; Shumaker R; Aghajanian C; Taylor M
Lancet Oncol; 2019 May; 20(5):711-718. PubMed ID: 30922731
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Efficacy and Safety of Anti-Programmed Cell Death-1 Antibody Plus Lenvatinib and Chemotherapy as First-Line Therapy for Patients with Stage IV Gallbladder Cancer: A Real-World Study in a Chinese Population.
Wu T; Pu C; Wang Q; Zhang K
Biomedicines; 2023 Oct; 11(11):. PubMed ID: 38001934
[No Abstract] [Full Text] [Related]
20. Lenvatinib Plus Camrelizumab versus Lenvatinib Monotherapy as Post-Progression Treatment for Advanced Hepatocellular Carcinoma: A Short-Term Prognostic Study.
Wei F; Huang Q; He J; Luo L; Zeng Y
Cancer Manag Res; 2021; 13():4233-4240. PubMed ID: 34079375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]